BACKGROUND: The relationship between marijuana use and cardiovascular health remains uncertain, with several observational studies suggesting a potential association with increased adverse atherosclerotic cardiovascular disease (ASCVD) outcomes. This study examined the relationship between marijuana use, ASCVD risk factors, and cardiometabolic risk profiles. METHODS: US adults (18–59 years) without cardiovascular disease were identified from the National Health And Nutrition Examination Survey (2005–2018) based on self-reported marijuana use. Current users (used within the past month) and never users were compared with assess the burden and control of traditional ASCVD risk factors and biomarkers, using inverse probability of treatment weighting to adjust for sociodemographic and lifestyle factors, including tobacco use. RESULTS: Of the 13 965 participants identified (mean age, 37.5; 51.2% female; 13% non-Hispanic Black), 26.6% were current users. Current users were predominantly male, low-income, and more likely to be concurrent tobacco users. Inverse probability of treatment weighting analysis showed no significant differences in the burden and control of hypertension (19.3% versus 18.8%, P =0.76; 79.8% versus 77.8%, P =0.75), dyslipidemia (24.0% versus 19.9%, P =0.13; 82% versus 75%, P =0.95), diabetes (4.8% versus 6.4%, P =0.19; 52.9% versus 50.6%, P =0.84), obesity (35.8% versus 41.3%, P =0.13), and physical activity levels (71.9% versus 69.3%, P =0.37) between current and never users. Likewise, mean 10-year ASCVD risk scores (2.8% versus 3.0%, P =0.49), 30-year Framingham risk scores (22.7% versus 24.2%, P =0.25), and cardiometabolic profiles including high-sensitivity C-reactive protein (3.5 mg/L versus 3.7 mg/L, P =0.65), neutrophil-lymphocyte ratio (2.1 versus 2.1, P =0.89), low-density lipoprotein (114.3 mg/dL versus 112.2 mg/dL, P =0.53), total cholesterol (191.2 mg/dL versus 181.7 mg/dL, P =0.58), and hemoglobin A1C (5.4% versus 5.5%, P =0.25) were similar between current and never users. CONCLUSIONS: This cross-sectional study found no association between self-reported marijuana use and increased burden of traditional ASCVD risk factors, estimated long-term ASCVD risk, or cardiometabolic profiles. Further studies are needed to explore potential pathways between adverse cardiovascular disease outcomes and marijuana use.

中文翻译：

---

当前和从未吸食大麻者之间动脉粥样硬化心血管危险因素和心脏代谢特征的比较

背景：大麻使用与心血管健康之间的关系仍不确定，一些观察性研究表明大麻与动脉粥样硬化性心血管疾病（ASCVD）不良结局的增加存在潜在关联。这项研究探讨了大麻使用、ASCVD 危险因素和心脏代谢风险状况之间的关系。 方法：根据自我报告的大麻使用情况，通过国家健康和营养检查调查（2005-2018）确定了没有心血管疾病的美国成年人（18-59岁）。将当前用户（过去一个月内使用过）和从未使用过的用户进行比较，评估传统 ASCVD 风险因素和生物标志物的负担和控制，使用治疗权重的逆概率来调整社会人口统计和生活方式因素（包括烟草使用）。 结果：在确定的 13,965 名参与者中（平均年龄 37.5 岁；51.2% 为女性；13% 为非西班牙裔黑人），26.6% 是当前用户。目前的使用者主要是男性、低收入者，而且更有可能是同时吸烟的人。治疗权重分析的逆概率显示，高血压的负担和控制没有显着差异（19.3% vs 18.8%，磷=0.76；79.8% 对比 77.8%，磷=0.75），血脂异常（24.0% vs 19.9%，磷=0.13；82% 与 75%，磷=0.95）、糖尿病（4.8% vs 6.4%，磷=0.19；52.9% 对比 50.6%，磷=0.84），肥胖（35.8% vs 41.3%，磷=0.13）和体力活动水平（71.9% 对比 69.3%，磷=0.37) 当前用户和从未用户之间。同样，平均 10 年 ASCVD 风险评分（2.8% 与 3.0%，磷=0.49），30 年 Framingham 风险评分（22.7% 对比 24.2%，磷=0.25），以及包括高敏 C 反应蛋白（3.5 mg/L 与 3.7 mg/L，磷=0.65），中性粒细胞-淋巴细胞比率（2.1 与 2.1，磷=0.89），低密度脂蛋白（114.3 mg/dL 对比 112.2 mg/dL，磷=0.53），总胆固醇（191.2 mg/dL 对比 181.7 mg/dL，磷=0.58）和血红蛋白 A1C（5.4% 对比 5.5%，磷=0.25）在当前用户和从未使用过的用户之间相似。 结论：这项横断面研究发现，自我报告的大麻使用与传统 ASCVD 危险因素负担增加、估计的长期 ASCVD 风险或心脏代谢特征之间没有关联。需要进一步的研究来探索不良心血管疾病结果与大麻使用之间的潜在途径。